These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17332346)

  • 41. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
    Fung AS; Wu L; Tannock IF
    Clin Cancer Res; 2009 Sep; 15(17):5389-95. PubMed ID: 19706800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
    Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
    Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
    Patel V; Marsh CA; Dorsam RT; Mikelis CM; Masedunskas A; Amornphimoltham P; Nathan CA; Singh B; Weigert R; Molinolo AA; Gutkind JS
    Cancer Res; 2011 Nov; 71(22):7103-12. PubMed ID: 21975930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mammalian target of rapamycin and head and neck squamous cell carcinoma.
    Liao YM; Kim C; Yen Y
    Head Neck Oncol; 2011 Apr; 3():22. PubMed ID: 21513566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
    Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
    Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
    Wang JY; Jin X; Zhang X; Li XF
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1191-1196. PubMed ID: 29402408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma.
    Nguyen SA; Walker D; Gillespie MB; Gutkind JS; Day TA
    Curr Treat Options Oncol; 2012 Mar; 13(1):71-81. PubMed ID: 22282394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
    Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
    Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
    Yang L; Clarke MJ; Carlson BL; Mladek AC; Schroeder MA; Decker P; Wu W; Kitange GJ; Grogan PT; Goble JM; Uhm J; Galanis E; Giannini C; Lane HA; James CD; Sarkaria JN
    Clin Cancer Res; 2008 Jun; 14(12):3993-4001. PubMed ID: 18559622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
    Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.
    Hall B; Nakashima H; Sun ZJ; Sato Y; Bian Y; Husain SR; Puri RK; Kulkarni AB
    J Transl Med; 2013 Feb; 11():45. PubMed ID: 23421960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current development of mTOR inhibitors as anticancer agents.
    Faivre S; Kroemer G; Raymond E
    Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
    Jimeno A; Kulesza P; Wheelhouse J; Chan A; Zhang X; Kincaid E; Chen R; Clark DP; Forastiere A; Hidalgo M
    Br J Cancer; 2007 Mar; 96(6):952-9. PubMed ID: 17342092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
    Italiano A; Kind M; Stoeckle E; Jones N; Coindre JM; Bui B
    Anticancer Drugs; 2011 Jun; 22(5):463-7. PubMed ID: 21301319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
    Ekshyyan O; Moore-Medlin TN; Raley MC; Sonavane K; Rong X; Brodt MA; Abreo F; Alexander JS; Nathan CA
    BMC Cancer; 2013 Jul; 13():320. PubMed ID: 23815869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.